Pluristem Therapeutics Inc, a developer of placenta-based cell therapy products, said the US Patent and Trademark Office (USPTO) issued a patent titled “Skeletal muscle regeneration using mesenchymal system cells.”
“This key patent, which has already been granted in Europe, Hong Kong and Israel, addresses the use of MSCs for skeletal muscle regeneration used either directly after, or shortly after, post-surgical muscle injury,” said Pluristem.
“The company received positive feedback from the U.S. Food and Drug Administration (FDA) and the European Medicine Agency (EMA) for the proposed study design and endpoints of its Phase III trial for the treatment of muscle recovery following arthroplasty for hip fracture.
“This planned study was recently awarded an $8.7 million grant by the Horizon 2020 program, the European Union’s largest research and innovation program.
“If successful, Pluristem plans to use the study results to achieve marketing approval in both the U.S. and Europe.”
Pluristem Co-CEO Zami Aberman said: “This very important patent comes at the right time, just ahead of our planned Phase III study in muscle regeneration following hip fracture.
“The patent substantially strengthens our intellectual property around muscle regeneration, particularly as it pertains to repair and regeneration following surgery.
“In an industry that demands constant technological and scientific advances, a robust patent portfolio covering our core innovations strengthens Pluristem’s competitive edge.”